RegenETP, Inc. Share Price

Stocks

02/09/25	PolarityBio Announces Launch of Expanded Access Treatment Protocol to Provide Continued Access to SkinTE for Patients with Wagner 1 Diabetic Foot Ulcers	CI
26/08/25	PolarityBio Completes Enrollment in the Phase III Pivotal Study of SkinTE for Diabetic Foot Ulcers	CI
19/05/24	RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC	CI
26/02/24	PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers	CI
18/08/23	PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer	CI
18/08/23	PolarityTE, Inc. Announces Executive Changes	CI
18/08/23	PolarityTE, Inc. has Changed its Name to RegenETP, Inc	CI
14/08/23	Grander Acquisition LLC completed the acquisition of Substantially all of the assets of PolarityTE, Inc..	CI
01/08/23	PolarityTE, Inc. Announces the Resignation of Jeff Dyer from the Company's Board of Directors	CI
15/06/23	PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite Index	CI
13/06/23	PolarityTE, Inc.(NasdaqCM:PTE) dropped from S&P TMI Index	CI
06/06/23	Grander Acquisition LLC entered into a stalking horse asset purchase agreement to acquire Substantially all of the assets of PolarityTE, Inc. for $6.5 million.	CI
12/05/23	PolarityTE, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

28/12/22	Northland Securities Adjusts Price Target on PolarityTE to $1 From $1.25, Maintains Outperform Rating	MT
31/03/22	Cantor Fitzgerald Downgrades PolarityTE to Neutral From Overweight, Adjusts Price Target to $1 From $2.50	MT

15/08/23	PolarityTE : Acquisition/Asset Disposal - Form 8-K	PU
07/06/23	POLARITYTE, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
07/06/23	POLARITYTE, INC. : Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
26/04/23	POLARITYTE, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
27/03/23	POLARITYTE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	AQ

1 day

-8.24%

Manager	Title	Age	Since
Nikolai Sopko CTO	Chief Tech/Sci/R&D Officer	-	-
Ryan Mathis CTO	Chief Tech/Sci/R&D Officer	-	31/08/2021
Stephen Milner CTO	Chief Tech/Sci/R&D Officer	-	29/03/2017

Date	Insider	Type	Main position	Quantity	% Market Cap.
26/01/23	Jeffrey Dyer	Other	Director	11,872	0.1641%
26/01/23	Jeffrey Dyer	Free	Director	42,986	0.5942%
12/01/23	Christian Nolet	Fiscal year	Director	39,575	0.5470%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENETP, INC.	-8.24%	+0.65%	-	-	1.12M
CHURCHILL CAPITAL CORP XI	-2.75%	-17.21%	-	-	812M
CENTIEL AG	-6.81%	-11.73%	+277.19%	-75.92%	658M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	0.00%	+0.20%	-	-	646M
BAIN CAPITAL GSS INVESTMENT CORP.	-0.39%	-0.10%	-	-	600M
CHURCHILL CAPITAL CORP XII	+0.19%	-0.19%	-	-	595M
CANTOR EQUITY PARTNERS IV, INC.	+0.44%	+0.34%	+2.52%	-	591M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.90%	+0.78%	-	-	578M
CHURCHILL CAPITAL CORP XIII	+0.19%	+0.19%	-	-	508M
Average	-1.91%	-2.59%	+139.86%	-75.92%	623.41M
Weighted average by Cap.	-1.26%	-3.22%	+147.20%	-75.92%